Voyageur appointed Fluor to assess iodine and barium projects, advancing integrated North American contrast media production through strategic collaboration with Bayer.
Voyageur Pharmaceuticals Ltd., headquartered in Cochrane, Alberta, has announced the appointment of Fluor Corporation, a globally recognized engineering, procurement, construction, and maintenance (EPCM) company based in Irving, Texas, to carry out comprehensive feasibility studies for two major projects aimed at strengthening North America’s supply chain for radiology contrast media. The initiative marks another significant step in Voyageur’s strategy to establish a fully integrated domestic production platform for pharmaceutical-grade iodine and barium contrast agents used in medical imaging.
The first feasibility study will focus on Voyageur’s proposed iodine extraction and production facility in Oklahoma, United States. The project forms part of the company’s ongoing collaboration with Bayer AG and is designed to evaluate the technical and economic viability of producing pharmaceutical-grade iodine using Voyageur’s patent-pending Meuller extraction process. The proprietary technology, announced earlier this year, has been developed in partnership with Bayer under a milestone-based funding agreement. The planned facility will extract high-purity iodine from iodine-rich oilfield brine, creating a reliable domestic source of a critical raw material used in the manufacture of diagnostic contrast media. By reducing reliance on imported iodine supplies, the project aims to improve supply chain resilience while supporting the growing demand for medical imaging products across North America.
The second feasibility study will evaluate Voyageur’s proposed integrated iodine and barium contrast drug manufacturing facility. According to the company, this pharmaceutical manufacturing plant is expected to produce finished contrast media products using both iodine and barium. A key feature of the project is the integration of high-purity barite sourced from Voyageur’s wholly owned Frances Creek barium deposit in British Columbia with domestically produced iodine. Through this vertically integrated approach, Voyageur intends to create what it describes as North America’s first "Earth-to-Bottle" manufacturing platform for radiology contrast agents, covering the complete value chain from raw mineral extraction to finished pharmaceutical products.
To support the development of these projects, Voyageur has allocated approximately US$2.35 million for the completion of the feasibility study related to the Bayer-supported iodine initiative. The budget for the integrated iodine and barium manufacturing facility will be finalized after additional testing of the company’s proprietary Streamline iodine drug manufacturing process is completed. This phased approach is intended to ensure that technical validation is achieved before determining the full scope and investment requirements for the pharmaceutical production facility.
Fluor’s involvement is expected to provide extensive expertise in process engineering, facility design, project economics, and large-scale industrial project execution. The company will assess technical, environmental, financial, and regulatory aspects of both projects to ensure they meet the standards necessary for attracting project financing and obtaining regulatory approvals. Completion of the feasibility studies is anticipated in early 2027, after which Voyageur expects to evaluate whether to proceed with construction later that year.
Commenting on the partnership, Brent Willis, Chief Executive Officer of Voyageur Pharmaceuticals, stated that working with Fluor represents an important milestone in reducing project risk and accelerating development timelines. He emphasized that the combination of Voyageur’s iodine initiative, Bayer’s collaboration, and Fluor’s engineering capabilities positions the company to strengthen North America’s supply of essential medical imaging ingredients. According to Willis, the projects support Voyageur’s long-term objective of becoming the continent’s first fully integrated producer of both barium- and iodine-based contrast media.
These developments build upon Voyageur’s recent commercial achievements, including the launch of Health Canada-approved barium contrast products that are already generating revenue. The company also continues to advance its strategic partnership with Bayer. Upon successful completion of the feasibility study and subject to further agreements between both parties, Voyageur and Bayer may move into the next phase of development under an offtake-linked production financing model. Under such an arrangement, Bayer could potentially provide capital funding for the iodine production facility, while Voyageur would retain responsibility for operating and managing the project under definitive commercial agreements. This collaborative framework could accelerate project implementation while strengthening North America’s long-term supply of critical medical imaging contrast agents.
Impact on Products and Chemical Commodity Prices
The announcement is expected to have a positive long-term impact on the supply of iodine, barium sulfate (barite), and radiology contrast media, although immediate market effects are likely to remain limited since both projects are still in the feasibility stage. If implemented, Voyageur Pharmaceuticals' vertically integrated production model could reduce North America's dependence on imported iodine and strengthen regional supply security for pharmaceutical-grade iodine and barium-based contrast agents. This may improve raw material availability and enhance supply chain resilience for medical imaging products.
For the chemical commodities tracked by ChemAnalyst, iodine prices are expected to remain largely stable in the short term because no additional production capacity has been commissioned yet. Over the longer term, successful commercialization could ease supply constraints, potentially exerting downward pressure on North American iodine prices. Barite (barium sulfate) prices are also expected to remain stable initially, with modest support for demand as domestic pharmaceutical-grade consumption increases alongside future production capacity.
